about us
soloMER® technology
pipeline
licensing opportunities
our mission
To deliver and commercialise effective therapeutics for improved patient treatment of cancer and inflammatory diseases.
our vision
To improve the outcomes and quality of life for people combating disease now, and in the future.
our values
Development of therapeutics for patient benefit. Strong science to deliver effective therapeutics.
Individual challenge for collective success. Strength through diversity.


leading the way with soloMER® technology
soloMERs® are small (approximately 11 kDa) and stable proteins that have squeezed a fourth binding loop into their single domain format and crucially are derived evolutionarily from a non-antibody lineage, placing them outside the complex/competitive antibody patent landscape.
soloMERs® are superior to, and differentiated from more traditional antibody platforms as they are pre-disposed to bind cryptic, more occluded epitopes such as recessed active site pockets and grooves in protein targets.

license our patented inventions and proprietary products
Elasmogen has succeeded in isolating high affinity, highly selective and differentiated, patent protected soloMERs® against a number of different target classes demonstrating the power of our platforms. We are actively looking for potential partners who would like to license our products and/or gain access to our proprietary technology platforms for de novo selection campaigns.